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Abstract
Background: Amyloid accumulation in the brain parenchyma is a hallmark of Alzheimer’s disease (AD) and is seen
in normal aging. Alterations in cerebrospinal fluid (CSF) dynamics are also associated with normal aging and AD.
This study analyzed CSF volume, production and turnover rate in relation to amyloid-beta peptide (Ab)
accumulation in the aging rat brain.
Methods: Aging Fischer 344/Brown-Norway hybrid rats at 3, 12, 20, and 30 months were studied. CSF production
was measured by ventriculo-cisternal perfusion with blue dextran in artificial CSF; CSF volume by MRI; and CSF
turnover rate by dividing the CSF production rate by the volume of the CSF space. Ab40 and Ab42 concentrations
in the cortex and hippocampus were measured by ELISA.
Results: There was a significant linear increase in total cranial CSF volume with age: 3-20 months (p < 0.01); 3-30
months (p < 0.001). CSF production rate increased from 3-12 months (p < 0.01) and decreased from 12-30 months
(p < 0.05). CSF turnover showed an initial increase from 3 months (9.40 day
-1) to 12 months (11.30 day
-1) and then
a decrease to 20 months (10.23 day
-1) and 30 months (6.62 day
-1). Ab40 and Ab42 concentrations in brain
increased from 3-30 months (p < 0.001). Both Ab42 and Ab40 concentrations approached a steady state level by
30 months.
Conclusions: In young rats there is no correlation between CSF turnover and Ab brain concentrations. After 12
months, CSF turnover decreases as brain Ab continues to accumulate. This decrease in CSF turnover rate may be
one of several clearance pathway alterations that influence age-related accumulation of brain amyloid.
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Background
The cerebrospinal fluid (CSF) circulation is critical to
maintaining a healthy environment for the brain, and its
functional decline with normal aging and the age-related
dementias remains of particular interest and concern.
For example, there is decreased CSF production and
turnover, diminished clearance of proteins, peptides and
other potentially toxic metabolites, altered ion and
solute transport, and decreased resistance to oxidative
stress [1-3]. CSF is secret e dm a i n l yb yt h ec h o r o i d
plexus (CP) as an ultrafiltrate of blood. It circulates
through the cerebral ventricles, leptomeninges, and
along central nervous system (CNS) surfaces, reentering
the bloodstream, in humans, at the arachnoid villi [4].
In rodents there appears to be a significant amount of
CSF absorption via the nasal lymphatics [5]. This con-
tinual CSF turnover, defined as the rate at which the
CSF volume is completely replaced, is considered to
play a key role in the clearance of many solutes from
the brain [4]. In human and animal models, CSF pro-
duction by the CP decreases by nearly 50 percent with
age [4,6]. The decrease is associated with striking mor-
phological alterations in the CP: flattening of CP
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any medium, provided the original work is properly cited.epithelial cells, fibrosis, and increased cellular inclusions
[3,7]. Total CSF volume has been shown to increase
with age, accompanied by brain atrophy [8]. It is not
surprising, then, that CSF turnover, calculated by divid-
ing the CSF production rate by the total CSF volume,
substantially decreases with age [3,9].
Reduced CSF turnover may have consequences for
clearance of many toxic peptides, proteins, and other
metabolites. Recently, it was found that albumin (a solu-
ble CSF protein) levels are elevated in elderly sheep
associated with decreased CSF production and turnover
[10]. Albumin accumulation in the CSF is typical of
other soluble proteins in the CSF which, with aging,
may increase as brain concentrations increase. By con-
trast, in cognitively normal aging human subjects amy-
loid-beta peptide (Ab) concentrations in the CSF vary
inversely with amyloid accumulation in the brain par-
enchyma, decreasing as brain Ab accumulates: a conse-
quence of self-assembly into insoluble fibrils and
plaques [11-13]. Lower than normal CSF concentration
of Ab42 is a biomarker for Alzheimer’sd i s e a s e( A D )
[14] The same inverse relationship between parenchy-
mal and CSF concentrations of Ab also appears in ani-
mal models of aging and AD [15-17]. Although wild-
type rats do not form fibrils and plaques as humans do,
there is self-assembly of Ab into oligomeric forms and
self-aggregation in the brain parenchyma as medium
and large granular formations when Ab concentrations
increase [18,19].
Enlarged cerebral ventricles and decreased CSF turn-
over are also associated with decreased CSF Ab concen-
trations in non-AD patients [20]. In several studies,
patients with normal pressure hydrocephalus, a disease
characterized by large ventricles and decreased CSF
turnover, presented with AD pathology [21]. Other stu-
dies have determined that Ab clearance is reduced in
AD subjects, whereas production is unchanged [22], and
that CSF Ab42 concentration is inversely related to ven-
tricular volume and CSF turnover [23]. Since aging is
the single most important risk factor for AD genesis
[24], and the relationship between CSF dynamics and
brain Ab accumulation has not been analyzed quantita-
tively, this study was designed to relate CSF production,
volume, and turnover to Ab concentration in the aging
Fischer 344/Brown-Norway (F344/BN) hybrid rat brain
at 3, 12, 20, and 30 months.
Methods
Animals
Male F344/BN hybrid rats aged 3, 12, 20, and 30
months were examined. F344/BN rats were chosen
because they are long-lived and available at most ages
up to 30 months from the National Institute of Aging
colony. Rats used to measure CSF production (n = 24)
were as e p a r a t eg r o u pfrom those used to measure
both CSF volume (n = 16) and Ab concentrations (n =
31). The rats were housed in the Central Animal Facility
at Rhode Island Hospital and had food and water ad
libitum. The Institutional Animal Care and Use Com-
mittee (IACUC) at Rhode Island Hospital approved all
experiments. Rats were euthanized by intra-peritoneal (i.
p.) pentobarbital (125 mg/kg) after the acute experi-
ments were completed. Rats used for ELISA measure-
ments were perfused with phosphate-buffered saline
(PBS) via left ventricular cannulation prior to removing
the brain.
CSF Volume Measurement
Total cranial and ventricular CSF volumes were mea-
sured using a Siemens 3T TIM Trio MR scanner. The
scanner was equipped with an AC88 high performance
gradient insert and a 4.5 cm custom volume transmit-
receive coil. Rats were imaged under continuous 1.8-
2.2% isoflurane anesthesia.T 1 - w e i g h t e dM P R A G Ed a t a
were acquired (slice thickness = 0.2 mm; field of view =
6 cm; matrix = 320 mm
3; TR = 2700 ms; TE = 3.89 ms;
inversion time = 900 ms; flip angle = 9 degrees; acquisi-
tion time = 12 min 38 s) for a total of 8 acquisitions.
All acquisitions were aligned to the original image and
averaged using the Analysis of Functional Neuroimages
(AFNI) software package [25]. Images were imported as
Neuroimaging Informatics Technology Initiative (NIfTI)
files into the image analyzer, Slicer 3D [26-28]. Slicer
3D includes a brightness/contrast function, a normal
zoom function, and a pixel-by-pixel magnifying glass
that allows the user to determine which pixels in the
T1-weighted images are gray or black. Fiducial marker
points were placed only on black pixels. From these
fiducial-marked images, the FastMarching Segmentation
module builds a 3D model from surrounding pixels with
the same gray scale value [29]. Ventricular CSF spaces
(lateral ventricles, third ventricle, cerebral aqueduct, and
fourth ventricle) and the subarachnoid space over the
brain were marked with fiducial points in each slice, and
total cranial CSF volume was calculated from the sum of
ventricular CSF and subarachnoid CSF volumes using
the FastMarching Segmentation module. Volume analy-
sis was performed by one reader for consistency.
CSF Production and Turnover Rate Calculation
CSF production was calculated as a function of dye-dilu-
tion using ventriculo-cisternal (V-C) perfusion with Blue
D e x t r a n2 0 0 0d y e( S i g m a ,S t .L o u i s ,M O ,U S A ) .C o m -
plete methodological details have been previously
described [30]. Briefly, the rats were anesthetized with i.
p. pentobarbital and immobilized in a stereotaxic frame.
Two stainless steel 27-gauge cannulae were inserted,
one into each lateral cerebral ventricle. Blue Dextran
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t h ec a n n u l a ea t2μl/min. A third cannula was inserted
into the cisterna magna for CSF collection. Intraventri-
cular pressures were monitored by T-connectors to the
infusion cannulae. CSF samples were collected every 20
min, and blue Dextran concentration was determined
using a spectrophotometer measuring absorbance at 620
nm. The rate of CSF formation was calculated using the
following formula: Vf =V i × [(Ci -C o)/Co], where V
represents the rate of CSF flow, C the concentration of
dye, and the subscripts f, i, and o represent formation,
inflow, and outflow [30]. CSF turnover was calculated
by dividing the mean CSF production (μl/min) by the
mean CSF volume (μl) in each age group and multiply-
ing by 1440 min/day, thus obtaining a turnover value in
day
-1.
Ab Accumulation
The fronto-parietal cortex plus the complete hippocam-
pal formation was excised from the rat brains post-per-
fusion with PBS. These samples were then thoroughly
ground into a powder over a bed of liquid nitrogen, and
250 mg of that powder was taken for the homogeniza-
tion and protein extraction. The concentration of Ab40
and Ab42 in cortical and hippocampal rat brain samples
was measured using a sandwich ELISA method. Details
can be found in our previous publication [31]. High-sen-
sitivity ELISA kits (Wako Chemicals, Catalog # 294-
64701 and 292-64501, Richmond, VA, USA) were cho-
sen to reduce background and to improve detection of
Ab40 (sensitivity: 0.049 pmol/L) and Ab42 (sensitivity:
0.024 pmol/L). Both kits employ a two binding site
sandwich ELISA system designed to specifically detect
Ab40 and Ab42. A monoclonal antibody directed
against Ab11- 28 (BNT77) was used as the capture anti-
body. It is designed to detect both full-length Ab as well
as Ab with a truncated or modified N-terminus. For
specific detection of Ab40, the monoclonal antibody
BA27 directed against the C-terminal portion of Ab40
was used, and for Ab42, BC05 directed against the C-
terminal portion of Ab42 was used. Total protein in
each sample was determined using a BCA Protein Assay
kit (Pierce, Rockford, IL, USA), with absorbance read at
562 nm. Total Ab concentrations were expressed as pg/
mg total protein.
Statistical Analysis
All statistics were conducted using GraphPad Prism
v4.01 (GraphPad Software, San Diego, CA, USA). Data
values for CSF volume and CSF production were first
subject to analysis of variance (ANOVA) and then to
Bonferroni’s multiple comparison test. CSF turnover was
calculated for each age group from the means of the
CSF production values and the CSF volume measure-
ments. Significance was set at p < 0.05.
Results
CSF Dynamics
Ventricular CSF volume (lateral, third, and fourth ven-
tricles) increased linearly with age, p <0 . 0 0 1 ,r
2 =0 . 7 2
(Figure 1A). The mean ± standard error of the mean
(SEM) ventricular CSF volume for rats at 3 months was
7.20 ± 1.6 μL (n = 4), at 12 months it was 16.2 ± 3.0 μL
(n = 4), at 20 months it was 29.5 ± 5.4 μL( n=4 ) ,a n d
at 30 months it was 33.6 ± 2.6 μL (n = 4). ANOVA, cor-
rected for multiple comparisons, revealed a significant
difference between 3 and 20 months (p <0 . 0 1 ) ,3a n d
30 months (p < 0.001), and 12 and 30 months (p <
0.05). Bonferroni’s method was used to adjust the level
of significance. Figure 2A shows a 3D model of ventri-
cular CSF volume.
Total cranial CSF volume also increased linearly with
age, p < 0.001, r
2 =0 . 9 9( F i g u r e1 B ) .T h em e a n±S E M
total cranial CSF volume for rats at 3 months of age
was 275 ± 21 μL (n = 4). The 12 month value was 321
±1 3μL (n = 4). The value at 20 months was 375 ± 30
μL (n = 4), and at 30 months it was 441 ± 45 μL( n=
4). ANOVA, corrected for multiple comparisons,
Figure 1 Age-related increase in CSF volume. A) Graph of ventricular CSF volume plotted against age (n = 4 for all age groups). Error bars
represent SEM. B) Graph of total cranial CSF volume plotted against age (n = 4 for all age groups). Error bars represent SEM. Note that both
ventricular and total cranial CSF volumes appear to increase linearly with age.
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months (p < 0.01), 3 and 30 months (p < 0.001), 12 and
30 months (p < 0.0001), and 20 and 30 months (p <
0.05). Bonferroni’s method was used to adjust the level
of significance. Figure 2B shows a 3D model of
subarachnoid CSF volume, and Figure 2C shows repre-
sentative T1-weighted MR images for the four age
groups taken at several coronal planes.
CSF production varied significantly with age, p <
0.0008 (Figure 3A). The mean ± SEM production rate
Figure 2 Total CSF volume. A) CSF in the ventricles was measured by placing fiducial points (pink dots) on black pixels within the region of
interest. FastMarching Segmentation in Slicer 3D generates a rough sketch of the region of interest (green areas), as well as a 3D model.
Volume is calculated from this model. B) Similar steps were taken to measure CSF in the subarachnoid space. All measurements were done by
one reader for consistency. C) T1-weighted MR images. Each row represents five coronal slices from one rat brain (top row = 3 month, second
row = 12 month, third row = 20 month, bottom row = 30 month). Images were magnified and brightened for printing purposes.
Figure 3 CSF production and turnover rate as a function of age. A) Graph of CSF production plotted against age (3 months, n = 6; 12
months, n = 8, 20 months, n = 3; 30 months, n = 7). Error bars represent SEM. B) Graph of CSF turnover plotted against age. CSF turnover is
calculated from the means of CSF production and volume measurements. Both production and turnover are non-linear and show an initial
increase to 12 months with a subsequent decrease to 30 months. Note the marked decrease in CSF turnover between 20 and 30 months
compared to the turnover rate prior to 20 months. The late turnover decrease is due, in large part, to the marked increase in CSF volume,
whereas the initial increase is influenced more by the CSF production rate.
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Page 4 of 8f o rr a t sa t3m o n t h sw a s1 . 7 7±0 . 0 5μL / m i n( n=6 ) ,a t
12 months it was 2.84 ± 0.25 μL/min (n = 8), at 20
months 2.66 ± 0.17 μL / m i n( n=3 ) ,a n da t3 0m o n t h s
2.00 ± 0.09 μL/min (n = 7). Production increased
between 3 and 12 months (p < 0.01) and decreased
between 12 and 30 months (p < 0.05). There was no sig-
nificant difference between 3 and 30 month, 3 and 20
month, and 12 and 20 month production rates (p >
0.05), although a continuous decreasing trend is appar-
ent from 12 to 30 months. CSF turnover increased initi-
ally between 3 and 12 months (9.41 day
-1 to 11.3 day
-1)
and then decreased to 20 months (10.23 day
-1)a n d
further to 30 months (6.62 day
-1) (Figure 3B).
Ab Accumulation and CSF Turnover Rate
The concentrations of parenchymal Ab42 and Ab40 in
specimens of cerebral cortex plus hippocampus
increased significantly with age (p < 0.001). The mean ±
SEM value for Ab42 in rats at 3 months was 1.65 ± 0.19
pg/mg total protein (tp) (n = 8), at 12 months 4.94 ±
1.11 pg/mg tp (n = 8), at 20 months 7.79 ± 0.57 pg/mg
tp (n = 8), and at 30 months 8.67 ± 0.13 pg/mg tp (n =
7). ANOVA with Bonferroni’s multiple comparison
adjustment revealed a significant difference between 3
and 12 months (p < 0.01), 3 and 20 months (p <0 . 0 0 1 ) ,
3a n d3 0m o n t h s( p < 0.001), 12 and 20 months (p <
0.05), and 12 and 30 months (p < 0.01). The mean ±
SEM value for Ab40 in 3 months old rats was 3.25 ±
0.23 pg/mg tp (n = 8), at 12 months 4.79 ± 0.39 pg/mg
tp (n = 8), at 20 months 5.58 ± 0.23 pg/mg tp (n = 8),
a n da t3 0m o n t h s5 . 6 6±0 . 3 2p g / m gt p( n=7 ) .T h e r e
was a significant difference between 3 and 12 months (p
< 0.01), 3 and 20 months (p < 0.001), and 3 and 30
months (p < 0.001). Ab42 and Ab40 concentration
increased rapidly between 3 and 12 months, followed by
a decreased rate of rise in Ab40 between 12 and 30
months, approaching a steady state between 20 and 30
months. Ab42 continued to rise to 20 months and then
t h er a t eo fi n c r e a s es l o w e dt o3 0m o n t h s .T h e r ew a sa
reversal of the Ab40/Ab42 ratio in brain parenchyma
with advancing age. Figure 4 shows the accumulation of
Ab40 and Ab42 plotted with the changes in CSF turn-
over with age.
Discussion
This study used aging F344/BN rats to temporally relate
CSF volume, production and turnover with brain Ab40
and Ab42 accumulation. A linear increase in ventricular
and total cranial CSF volumes with age and a non-linear
relationship between CSF production and age were
found. The CSF turnover rate estimates how many
times the entire CSF volume is replaced per day and
was found to increase from 3 to 12 months and
decrease from 12 to 30 months. The significant increase
in CSF production from 3 to 12 months and its subse-
quent decrease to 30 months highly influenced the
shape of the turnover curve. There was a rapid increase
of cortical and hippocampal Ab40 and Ab42 to about
12 months, after which the rate of increase in Ab40 slo-
wed. Ab42 continued on the same rising slope to 20
months after which the slope decreased. Both Ab40 and
Ab42 approached a steady state concentration in the
Figure 4 Graphs of the concentration of Ab40 and Ab42 in cerebral cortex plus hippocampus, and CSF turnover plotted against age.
Ab40 (dashed line, diamonds) and Ab42 (solid line, squares) in pg/mg total protein concentrations are plotted on the left ordinate (3 months, n
= 8; 12 months, n = 8; 20 months, n = 8; 30 months, n = 7). CSF turnover (dotted line, circles) is plotted on the right ordinate. Error bars for Ab
are SEM. CSF turnover is calculated from the means of CSF production and volume measurements. Note that Ab40 and Ab42 concentrations
increase before there is a significant decrease in CSF turnover. Only later (after 12 months) in the lifespan of the F344/BN rat is there an inverse
relationship between Ab accumulation and the CSF turnover rate.
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ratio in the brain with advancing age was an interesting
finding.
The cranial CSF spaces were imaged by MRI. Fiducial
points were placed within these spaces to construct a
3D model of the lateral, third, and fourth ventricles, and
the subarachnoid space around the brain to calculate
total CSF volume. Some measurement error may have
been introduced by the observer; however, it would have
been consistent throughout the age groups, and our
results are within the range of measurements reported
by others for ventricular and total cranial CSF volumes
[32-35].
Determining the causes of Ab accumulation in the
brain with aging may be crucial to the development of
effective AD therapies. Ab accumulates as a result of an
imbalance between production and clearance [22]. Stu-
dies suggest that overall brain Ab accumulation in aging
a n di nA Di sn o td u et oa ni n c r e a s ei nA b production,
but rather a decrease in Ab clearance from the brain
[22,31,36], although some increase in production cannot
be completely excluded by these studies. Several path-
ways for Ab clearance exist: i) active transport via recep-
tors at the blood-brain barrier (BBB) and blood-CSF
barrier (BCSFB), ii) in situ enzymatic degradation and
iii) CSF bulk flow and turnover.
Previous reports have shown Ab clearance pathway
alterations with age. There is a significant decrease in
Ab efflux transporter expression with age and an
increase in influx transporter expression at the BBB
[31,36]. Interestingly, the opposite trend is true for Ab
transporter expression at the BCSFB, perhaps a compen-
satory response to the overall decrease in BBB Ab clear-
ance [37]. Studies have also shown decreases in Ab-
degrading enzymes with age [38]. CSF turnover, there-
fore, may become increasingly more important for meta-
bolite clearance in the aging brain [4].
CSF turnover is a modulator of CSF and brain protein
concentrations [9,10]. Although it appears that there is
no association between Ab accumulation in brain par-
enchyma and CSF turnover rates in the young rats,
there may be an inverse relationship between the two in
the elderly rats, as part of an age-related multi-factorial
decrease in Ab clearance via the BBB and CSF systems.
Clearly, Ab concentrations in brain increase while CSF
production and turnover increase up to 12 months of
age. Preston (2001) also found that Ab begins to accu-
mulate before there is any decrease in CSF production
and turnover [3]. However, CSF turnover in association
with other age-dependent Ab clearance defects may
contribute to the overall increase in Ab brain concentra-
tions with advancing age. This temporal association
between Ab and CSF dynamics in the older rats does
not prove a cause and effect relationship, but one may
argue that the decrease in CSF turnover is a contribut-
ing factor. Improving CSF turnover by shunting these
rats may show a causal relationship between the two if
shunting lowers the rate of Ab accumulation in aging.
Such a study would require measurement of brain, CSF
and blood Ab concentrations in both shunted and
sham-operated age-matched controls.
The procedure for measuring CSF production, V-C
perfusion, is extremely invasive, and the rats experienced
high mortality rates, particularly in the elderly. However,
the number of rats at 3 and 12 months was sufficient
for showing a significant rise in CSF production, and
the decrease from 12 to 30 months fits with existing
studies [3,9,10]. In a study by Preston (2001) using
Fischer 344 inbred rats, CSF production was shown to
increase from 3 to 19 months (1.21 ± 0.27 to 1.48 ±
0.53 μL/min) and then significantly decrease to 30
months (0.65 ± 0.16 μL/min). A 12 month measurement
was not included in this study, but judging from our
data (see Figure 3A) it would likely have been higher
than the 19 month production rate [3]. Because this
study and the Preston study used similar rat strains and
found similar production results, we believe that the
technical difficulties associated with our methods are
not substantive.
Conclusion
There is an increase in CSF production and turnover
from 3 to 12 months in this rat aging model at a time
when Ab concentrations increase, showing that before
12 months of age there is no relationship between amy-
loid deposition in the brain and CSF production and
turnover alterations. CSF turnover is inversely related to
brain Ab accumulation in elderly rats. The decreasing
CSF turnover rate in older rats suggests a possible ther-
apeutic target to improve CSF solute clearance by shunt
insertion in the aging F344/BN rat.
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